Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Alexion Pharm Inc 121 SEAPORT BOULEVARD BOSTON MA 02210 USA

www.alexion.com P: 475-230-2596 F: 203-271-8198

Description:

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

Key Statistics

Overview:

Market Capitalization, $K 40,335,968
Shares Outstanding, K 221,019
Annual Sales, $ 6,070 M
Annual Net Income, $ 603,400 K
Last Quarter Sales, $ 1,637 M
Last Quarter Net Income, $ 636,000 K
60-Month Beta 1.25
% of Insider Shareholders 4.03%
% of Institutional Shareholders 82.94%
Float, K 212,112
% Float 95.97%

Growth:

1-Year Return 66.61%
3-Year Return 38.44%
5-Year Return 41.91%
5-Year Revenue Growth 133.09%
5-Year Earnings Growth 154.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 3.52 on 04/30/21
Next Earnings Date 07/29/21
Earnings Per Share ttm 11.91
EPS Growth vs. Prev Qtr 19.49%
EPS Growth vs. Prev Year 7.62%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 05/23/11

ALXN Ratios

Ratio
Price/Earnings ttm 15.07
Price/Earnings forward 13.96
Price/Earnings to Growth 0.93
Return-on-Equity % 23.43%
Return-on-Assets % 15.06%
Profit Margin % 9.94%
Debt/Equity 0.19
Price/Sales 6.53
Price/Cash Flow 8.00
Price/Book 3.24
Book Value/Share 56.24
Interest Coverage 6.43
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar